SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA - Archive ouverte HAL Access content directly
Journal Articles Nephrology Dialysis Transplantation Year : 2020

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (6) , (8) , (9, 10, 11) , (12) , (13, 14) , (15) , (16, 17) , (18) , (19)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

Abstract

No abstract available
Fichier principal
Vignette du fichier
gfz137.pdf (49.24 Ko) Télécharger le fichier

Dates and versions

inserm-03261177 , version 1 (15-06-2021)

Licence

Attribution - NonCommercial - CC BY 4.0

Identifiers

Cite

P. Sarafidis, C. J. Ferro, E. Morales, A. Ortiz, J. Malyszko, et al.. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2020, 35 (10), pp.1825. ⟨10.1093/ndt/gfz137⟩. ⟨inserm-03261177⟩
19 View
331 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More